Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys

M. Feher, B. Gaszner, A. Tamás, A. L. Gil-Martinez, E. Fernandez-Villalba, M. T. Herrero, D. Reglodi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a well-known neuropeptide with strong neurotrophic and neuroprotective effects. PACAP exerts its protective actions via three G protein-coupled receptors: the specific Pac1 receptor (Pac1R) and the Vpac1/Vpac2 receptors, the neuroprotective effects being mainly mediated by the Pac1R. The protective role of PACAP in models of Parkinson’s disease and other neurodegenerative diseases is now well-established in both in vitro and in vivo studies. PACAP and its receptors occur in the mammalian brain, including regions associated with Parkinson’s disease. PACAP receptor upregulation or downregulation has been reported in several injury models or human diseases, but no data are available on alterations of receptor expression in Parkinson’s disease. The model closest to the human disease is the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced macaque model. Therefore, our present aim was to evaluate changes in Pac1R expression in basal ganglia related to Parkinson’s disease in a macaque model. Monkeys were rendered parkinsonian with MPTP, and striatum, pallidum, and cortex were evaluated for Pac1R immunostaining. We found that Pac1R immunosignal was markedly reduced in the caudate nucleus, putamen, and internal and external parts of the globus pallidus, while the immunoreactivity remained unchanged in the cortex of MPTP-treated parkinsonian monkey brains. This decrease was attenuated in some brain areas in monkeys treated with l-DOPA. The strong, specific decrease of the PACAP receptor immunosignal in the basal ganglia of parkinsonian macaque monkey brains suggests that the PACAP/Pac1R system may play an important role in the development/progression of the disease.

Original languageEnglish
Pages (from-to)702-715
Number of pages14
JournalNeurotoxicity Research
Volume33
Issue number4
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Macaca
Basal Ganglia
Pituitary Adenylate Cyclase-Activating Polypeptide
Haplorhini
Parkinson Disease
Globus Pallidus
Brain
Neuroprotective Agents
Caudate Nucleus
Putamen
G-Protein-Coupled Receptors
Neuropeptides
Neurodegenerative Diseases
Disease Progression
Neurodegenerative diseases
Up-Regulation
Down-Regulation

Keywords

  • Caudate
  • Cortex
  • PACAP
  • Pallidum
  • Parkinson’s disease
  • Putamen

ASJC Scopus subject areas

  • Neuroscience(all)
  • Toxicology

Cite this

Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys. / Feher, M.; Gaszner, B.; Tamás, A.; Gil-Martinez, A. L.; Fernandez-Villalba, E.; Herrero, M. T.; Reglodi, D.

In: Neurotoxicity Research, Vol. 33, No. 4, 01.05.2018, p. 702-715.

Research output: Contribution to journalArticle

Feher, M. ; Gaszner, B. ; Tamás, A. ; Gil-Martinez, A. L. ; Fernandez-Villalba, E. ; Herrero, M. T. ; Reglodi, D. / Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys. In: Neurotoxicity Research. 2018 ; Vol. 33, No. 4. pp. 702-715.
@article{74fbdc3cb2904160b4e4bf05120fc3db,
title = "Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys",
abstract = "Pituitary adenylate cyclase-activating polypeptide (PACAP) is a well-known neuropeptide with strong neurotrophic and neuroprotective effects. PACAP exerts its protective actions via three G protein-coupled receptors: the specific Pac1 receptor (Pac1R) and the Vpac1/Vpac2 receptors, the neuroprotective effects being mainly mediated by the Pac1R. The protective role of PACAP in models of Parkinson’s disease and other neurodegenerative diseases is now well-established in both in vitro and in vivo studies. PACAP and its receptors occur in the mammalian brain, including regions associated with Parkinson’s disease. PACAP receptor upregulation or downregulation has been reported in several injury models or human diseases, but no data are available on alterations of receptor expression in Parkinson’s disease. The model closest to the human disease is the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced macaque model. Therefore, our present aim was to evaluate changes in Pac1R expression in basal ganglia related to Parkinson’s disease in a macaque model. Monkeys were rendered parkinsonian with MPTP, and striatum, pallidum, and cortex were evaluated for Pac1R immunostaining. We found that Pac1R immunosignal was markedly reduced in the caudate nucleus, putamen, and internal and external parts of the globus pallidus, while the immunoreactivity remained unchanged in the cortex of MPTP-treated parkinsonian monkey brains. This decrease was attenuated in some brain areas in monkeys treated with l-DOPA. The strong, specific decrease of the PACAP receptor immunosignal in the basal ganglia of parkinsonian macaque monkey brains suggests that the PACAP/Pac1R system may play an important role in the development/progression of the disease.",
keywords = "Caudate, Cortex, PACAP, Pallidum, Parkinson’s disease, Putamen",
author = "M. Feher and B. Gaszner and A. Tam{\'a}s and Gil-Martinez, {A. L.} and E. Fernandez-Villalba and Herrero, {M. T.} and D. Reglodi",
year = "2018",
month = "5",
day = "1",
doi = "10.1007/s12640-017-9841-7",
language = "English",
volume = "33",
pages = "702--715",
journal = "Neurotoxicity Research",
issn = "1029-8428",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys

AU - Feher, M.

AU - Gaszner, B.

AU - Tamás, A.

AU - Gil-Martinez, A. L.

AU - Fernandez-Villalba, E.

AU - Herrero, M. T.

AU - Reglodi, D.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Pituitary adenylate cyclase-activating polypeptide (PACAP) is a well-known neuropeptide with strong neurotrophic and neuroprotective effects. PACAP exerts its protective actions via three G protein-coupled receptors: the specific Pac1 receptor (Pac1R) and the Vpac1/Vpac2 receptors, the neuroprotective effects being mainly mediated by the Pac1R. The protective role of PACAP in models of Parkinson’s disease and other neurodegenerative diseases is now well-established in both in vitro and in vivo studies. PACAP and its receptors occur in the mammalian brain, including regions associated with Parkinson’s disease. PACAP receptor upregulation or downregulation has been reported in several injury models or human diseases, but no data are available on alterations of receptor expression in Parkinson’s disease. The model closest to the human disease is the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced macaque model. Therefore, our present aim was to evaluate changes in Pac1R expression in basal ganglia related to Parkinson’s disease in a macaque model. Monkeys were rendered parkinsonian with MPTP, and striatum, pallidum, and cortex were evaluated for Pac1R immunostaining. We found that Pac1R immunosignal was markedly reduced in the caudate nucleus, putamen, and internal and external parts of the globus pallidus, while the immunoreactivity remained unchanged in the cortex of MPTP-treated parkinsonian monkey brains. This decrease was attenuated in some brain areas in monkeys treated with l-DOPA. The strong, specific decrease of the PACAP receptor immunosignal in the basal ganglia of parkinsonian macaque monkey brains suggests that the PACAP/Pac1R system may play an important role in the development/progression of the disease.

AB - Pituitary adenylate cyclase-activating polypeptide (PACAP) is a well-known neuropeptide with strong neurotrophic and neuroprotective effects. PACAP exerts its protective actions via three G protein-coupled receptors: the specific Pac1 receptor (Pac1R) and the Vpac1/Vpac2 receptors, the neuroprotective effects being mainly mediated by the Pac1R. The protective role of PACAP in models of Parkinson’s disease and other neurodegenerative diseases is now well-established in both in vitro and in vivo studies. PACAP and its receptors occur in the mammalian brain, including regions associated with Parkinson’s disease. PACAP receptor upregulation or downregulation has been reported in several injury models or human diseases, but no data are available on alterations of receptor expression in Parkinson’s disease. The model closest to the human disease is the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced macaque model. Therefore, our present aim was to evaluate changes in Pac1R expression in basal ganglia related to Parkinson’s disease in a macaque model. Monkeys were rendered parkinsonian with MPTP, and striatum, pallidum, and cortex were evaluated for Pac1R immunostaining. We found that Pac1R immunosignal was markedly reduced in the caudate nucleus, putamen, and internal and external parts of the globus pallidus, while the immunoreactivity remained unchanged in the cortex of MPTP-treated parkinsonian monkey brains. This decrease was attenuated in some brain areas in monkeys treated with l-DOPA. The strong, specific decrease of the PACAP receptor immunosignal in the basal ganglia of parkinsonian macaque monkey brains suggests that the PACAP/Pac1R system may play an important role in the development/progression of the disease.

KW - Caudate

KW - Cortex

KW - PACAP

KW - Pallidum

KW - Parkinson’s disease

KW - Putamen

UR - http://www.scopus.com/inward/record.url?scp=85037686474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037686474&partnerID=8YFLogxK

U2 - 10.1007/s12640-017-9841-7

DO - 10.1007/s12640-017-9841-7

M3 - Article

C2 - 29230633

AN - SCOPUS:85037686474

VL - 33

SP - 702

EP - 715

JO - Neurotoxicity Research

JF - Neurotoxicity Research

SN - 1029-8428

IS - 4

ER -